---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007740"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:52:23.217678+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports Q1 net loss $3.7M; DA-1726 shows 4.3% mean weight loss in Phase 1

## Summary
- Cash $11.2M at Q1-end; plus $10M private placement in May, funding into 2026.
- Net loss $3.7M ($0.36/sh) vs $6.7M ($1.32/sh) YoY; R&D spend down to $2.3M from $4.9M.
- DA-1726 (obesity) mean weight loss 4.3% at 32 mg at Day 26 (p=0.0005); max 6.3%; no titration needed.
- DA-1241 (MASH) Phase 2a reduced ALT 22.8 U/L at 16 weeks; end-of-Phase 2 FDA meeting expected H1 2025.
- Additional DA-1726 dose cohorts to start Q3 2025; data expected Q4 2025.

## SEC filing metadata
- accession: 0001558370-25-007740
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/0001558370-25-007740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007740
- JSON: https://secwatch.observer/filing/0001558370-25-007740.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.